# Junta clínica — PT-pseudo_b9f0b7018502 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_b9f0b7018502",
  "pid": "PT-pseudo_b9f0b7018502",
  "task": 1,
  "psa": 8.7,
  "age": 54,
  "months": 1,
  "pirads": "5",
  "psad": 0.4,
  "psav": 1.21,
  "psap": 7.0,
  "vol": 23.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.8609265,
  "medhx": "Coronary artery disease",
  "meds": "atorvastatin, metoprolol",
  "notes": "PSA 8.7 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 23 mL. csPCa 0.86.",
  "pmhx": [
    "Coronary artery disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "90 kg",
    "height": "182 cm",
    "bmi": "27.2",
    "bp": "97/85 mmHg",
    "hr": "82 bpm",
    "smoking": "Non-smoker",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "30 Jan 2025",
  "enc_ref": "Dr. L. Smits (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Ongoing monitoring of elevated prostate-specific antigen levels subsequent to a previously positive biopsy."
    },
    {
      "s": "History",
      "t": "An initial PSA elevation detected in mid-2022 prompted further investigation for this 54-year-old graphic designer. A subsequent targeted biopsy later established ISUP grade group 4 malignancy. He maintains a non-smoker status and shares his home with a partner, appreciating the adaptable nature of his self-employed design work. His coronary artery disease is managed with atorvastatin and metoprolol, and his most recent cardiology assessment noted stable angina with well-regulated lipid levels. He adheres to a daily 45-minute walking regimen while consuming alcohol in moderation. Lower urinary tract symptoms remain mild (IPSS 7/35), and a recent orthopaedic visit addressed a longstanding knee issue that continues to avoid surgical management. He has never married, listing his brother as his primary emergency contact."
    },
    {
      "s": "Physical examination",
      "t": "DRE reveals a prostate of uniform consistency and symmetry, devoid of nodular irregularities or focal asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable throughout the general assessment, which shows no peripheral lymphadenopathy or abdominal masses."
    }
  ],
  "occupation": "graphic designer",
  "marital": "Never married",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (brother)",
  "recent_other": [
    "Orthopaedic outpatient — knee follow-up"
  ],
  "alcohol": "5 units / week",
  "exercise": "Walking 45 min/day",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Maastricht UMC+",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_b9f0b7018502
Task: 1

Encounter: Urology - outpatient on 30 Jan 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 54-year-old male
  - PSA: 8.7 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.4 ng/mL²
  - PSA velocity: 1.21 ng/mL/yr
  - Prior PSA: 7.0 ng/mL
  - Prostate volume: 23.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8609265 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Coronary artery disease
  - Problem list / PMHx: Coronary artery disease
  - Current medication: atorvastatin, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 8.7 ng/mL. PI-RADS 5. PSAD 0.40. Prostate volume 23 mL. csPCa 0.86.

Vitals: weight 90 kg, height 182 cm, BMI 27.2, BP 97/85 mmHg, HR 82 bpm. Smoking: Non-smoker.

Chief complaint: Ongoing monitoring of elevated prostate-specific antigen levels subsequent to a previously positive biopsy.

History: An initial PSA elevation detected in mid-2022 prompted further investigation for this 54-year-old graphic designer. A subsequent targeted biopsy later established ISUP grade group 4 malignancy. He maintains a non-smoker status and shares his home with a partner, appreciating the adaptable nature of his self-employed design work. His coronary artery disease is managed with atorvastatin and metoprolol, and his most recent cardiology assessment noted stable angina with well-regulated lipid levels. He adheres to a daily 45-minute walking regimen while consuming alcohol in moderation. Lower urinary tract symptoms remain mild (IPSS 7/35), and a recent orthopaedic visit addressed a longstanding knee issue that continues to avoid surgical management. He has never married, listing his brother as his primary emergency contact.

Physical examination: DRE reveals a prostate of uniform consistency and symmetry, devoid of nodular irregularities or focal asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable throughout the general assessment, which shows no peripheral lymphadenopathy or abdominal masses.

Patient info: graphic designer; Never married; Lives with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 5 units / week; exercise Walking 45 min/day; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Orthopaedic outpatient — knee follow-up.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.69
  uncertainty  +/- 0.12 (95% CI 0.45-0.92); among patients it cannot tell apart the outcome was 0.90 of 1.00 mixed
  confidence   MODERATE — in this tier it was right 80% of the time over 20 labelled cases

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using a risk-based pathway based on PI-RADS score, PSA density, and prior biopsy status to guide the decision to perform a biopsy. It states, "In a contemporary series of biopsies, the likelihood of finding a csPCa after follow-up biopsy after a diagnosis of atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasia (PIN) was only 6-8% - not significantly different from follow-up biopsies after a negative biopsy."

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently informed by the guideline because it fails to account for the specific risk stratification variables the guideline uses, such as the PSA density threshold (0.15 ng/mL/cc) and the PI-RADS score, which are critical for risk-based decision-making. The bid is blind to the guideline's requirement to use these specific metrics to determine if a biopsy is warranted.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose is not provided, so I cannot assess if the lesion is unchanged or new, which is a factor the guideline makes decisive.
PSA trend - The PSA trend is 1.21 ng/mL/yr, which is a variable the guideline makes decisive regarding risk.
Previous notes - The previous notes state a prior biopsy established ISUP grade group 4 malignancy, which is an undocumented fact that is itself a finding, and the conference has to decide with it missing.
Laboratory results - The laboratory results show a PSA density of 0.4 ng/mL², which is a variable the guideline makes decisive regarding risk.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the specific risk stratification variables outlined in the EAU guideline, particularly the mpMRI prose and PSA trend, can override the prior positive biopsy result.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the mpMRI prose indicates a change in the lesion compared to the prior study.
  psa_trend (get_psa_trend) -> Confirm the PSA trend to assess risk stratification as per the guideline.
  previous_notes (get_previous_notes) -> Confirm the management context, specifically the finding that the prior biopsy established ISUP grade group 4 malignancy.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the mpMRI prose indicate a change in the lesion compared to the prior study?
  Q2. Does the PSA trend of 1.21 ng/mL/yr, in conjunction with the PSA density of 0.4 ng/mL², meet the threshold for a follow-up biopsy according to the EAU guideline?

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose indicates a finding of a discrete hypointense focus at the base-to-mid transition of the left posterior peripheral zone, spanning roughly 12 mm, with PI-RADS 5.
psa_trend
The PSA trend shows a value of 8.7 ng/mL in Jan 2025, following a previous value of 6.7 ng/mL in Jun 2024, indicating a rise of 2.0 ng/mL over the last 7 months.
previous_notes
The previous notes confirm that the prior biopsy established ISUP grade group 4 malignancy.

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator's questions did not specifically ask for them, and the key variables for the EAU guideline were addressed by the other retrieved documents.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose indicates a PI-RADS 5, which is a high-risk feature.
The PSA trend shows a rising trend, which is a variable the guideline makes decisive regarding risk.
AGAINST sampling this patient now
The prior positive biopsy result means the patient already has a tissue diagnosis.

WHERE THIS LEANS
The combination of a PI-RADS 5 and a rising PSA trend suggests a high-risk scenario that warrants further investigation according to the guideline's focus on risk stratification variables.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar answered Q1 by stating the mpMRI prose indicates a finding of a discrete hypointense focus at the base-to-mid transition of the left posterior peripheral zone, spanning roughly 12 mm, with PI-RADS 5. The answer to Q2 is not fully answered; the registrar confirmed the PSA trend but did not explicitly state whether the combination of the trend and PSA density meets the EAU threshold.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of BIOPSY because the registrar noted the PI-RADS 5 and the rising PSA trend, which are risk stratification variables the classifier considered.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the mpMRI prose indicate a change in the lesion compared to the prior study? Answered by the registrar, who stated the mpMRI prose indicates a finding of a discrete hypointense focus at the base-to-mid transition of the left posterior peripheral zone, spanning roughly 12 mm, with PI-RADS 5.
Q2. Does the PSA trend of 1.21 ng/mL/yr, in conjunction with the PSA density of 0.4 ng/mL², meet the threshold for a follow-up biopsy according to the EAU guideline? Not answered; the registrar confirmed the trend but did not confirm if the combined metrics meet the guideline threshold.

WHAT CARRIES WEIGHT, AND WHY
The two variables most relevant to the EAU guideline are the mpMRI prose because it assesses lesion change, and the PSA trend because it is a variable the guideline makes decisive regarding risk. The prior positive biopsy result is a variable the room has been leaning on that the guideline does not support, as the guideline focuses on risk stratification for *new* decisions.

MY SUGGESTION TO THE CHAIR
Given the PI-RADS 5 and the rising PSA trend, which are high-risk features according to the guideline, and the fact that the prior biopsy result is already established, the case is in a state to be decided based on the guideline's risk assessment. I suggest proceeding with a biopsy to further characterize the lesion.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Deferral is appropriate because the prior biopsy established an ISUP grade group 4 malignancy, meaning the disease is already characterized for management. Although the mpMRI showed a PI-RADS 5 and a rising PSA trend, the established prior diagnosis provides sufficient information to guide the next step. The prior positive biopsy result is the finding that justifies not proceeding with further sampling.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
